col blocks we are bridge builder col blocks
COVID answers in Scientific Journals all over the world


34 Results       Page 1

 [1] 
International Medical Press: Antiviral Therapy
  original article Date Title Authors   All Authors
1 [GO] 2025―Sep―10 Pharmacokinetic and mass balance characterization of [ 14 C] RAY1216, a SARS-CoV-2 M pro inhibitor, in healthy Chinese male subjects Wang Hu, Jiaxiang Ding, Yunqiu Xie, Tonghao Zhang, Yu Peng, Ying Wang, et al. (+10)
2 [GO] 2025―May―28 Magnolol inhibits viral replication and enhances antiviral immune responses against porcine reproductive and respiratory syndrome virus (PRRSV) in Marc-145 cells Shun Li, Mingzhan Zhu, Jingfei Deng, Yajuan Li, Yunfei Huang, Bikash R. Giri, et al. (+2)
3 [GO] 2025―Mar―26 Functional foods and immune system: A sustainable inhibitory approach against SARS-COV-2 Hubza Ruatt Khan, Rabia Sultan, Mehvish Javeed, Humaira Yasmeen, Iqra Arooj, Sara Janiad
4 [GO] 2025―Feb―18 Nirmatrelvir treatment duration and frequency of COVID-19 rebound Nathan Sudeep, Noah Kojima, Jeffrey D Klausner
5 [GO] 2025―Jan―21 Clinical outcomes among COVID-19 patients initiated on molnupiravir in Denmark - A national registry study Carsten S Larsen, Caroline L Westergaard, Nina B Stærke, Urs Arnet, Gui Liu, Line R Kantsø, Jakob Kjellberg
6 [GO] 2024―Dec―06 Repurposing FDA-approved drugs for COVID-19: targeting the main protease through multi-phase in silico approach Ahmed M Metwaly, Eslam B Elkaeed, Aisha A Alsfouk, Ibrahim M Ibrahim, Hazem Elkady, Ibrahim H Eissa
7 [GO] 2024―Jul―27 Clinical outcomes in patients with mild to moderate coronavirus disease 2019 treated with monoclonal antibody therapy versus an untreated control cohort Courtney N. Nichols, Mark Lustberg, Mohammed Mahdee E Sobhanie, Lucia J Niermann, Melissa Gordon, Nicholas Kman, et al. (+7)
8 [GO] 2024―Jun―14 Andrographolide suppresses SARS-CoV-2 infection by downregulating ACE2 expression: A mechanistic study Qing Li, Hongmei Lu, Yongdui Ruan, Yuxuan Geng, Zuguo Zhao, Ying Liu, et al. (+2)
9 [GO] 2024―Feb―14 Failure of bamlanivimab with selection of E484K mutation in an allogeneic stem cell transplant recipient with nosocomial SARS-CoV-2 infection Inès Boussen, Maud Salmona, Flore Sicre De Fontbrune, Aliénor Xhaard, Nathalie De Castro, Constance Delaugerre, et al. (+2)
10 [GO] 2023―Oct―20 Subacute thyroiditis following COVID-19 vaccination: Case presentation Aleksandra Z Tomic, Sonja S Zafirovic, Zoran M Gluvic, Vladimir S Samardzic, Mirjana T Macvanin, Maja LJ Radunovic, Esma R Isenovic
11 [GO] 2023―Sep―06 Computer-assisted drug discovery of potential natural inhibitors of the SARS-CoV-2 RNA-dependent RNA polymerase through a multi-phase in silico approach Eslam B Elkaeed, Bshra A Alsfouk, Tuqa H Ibrahim, Reem K Arafa, Hazem Elkady, Ibrahim M Ibrahim, et al. (+2)
12 [GO] 2023―Jun―29 Letter to the editor on use of antibodies from convalescent sera in the treatment of moderate and severe Covid-19 infection Sarah B Nahhal, Bassem Awada, Joe-David Azzo, Rayyan Wazzi-Mkahal, Souha Kanj, Zeina A Kanafani
13 [GO] 2022―Dec―21 A favipiravir-induced angioedema and urticaria in a COVID-19 patient Figen Ergur Ozturk, Ayperi Ozturk, Hale Ates
14 [GO] 2022―Apr―14 Synthetic Peptides outside the Spike Protein Heptad Repeat Regions as Potent Inhibitors of Sars-Associated Coronavirus Bo-Jian Zheng, Yi Guan, Ming-Liang He, Hongzhe Sun, Lanying Du, Ying Zheng, et al. (+13)
15 [GO] 2022―Apr―14 Indomethacin Has a Potent Antiviral Activity against Sars Coronavirus Carla Amici, Antonino Di Caro, Alessandra Ciucci, Lucia Chiappa, Concetta Castilletti, Vito Martella, et al. (+4)
16 [GO] 2022―Apr―14 Severe Acute Respiratory Syndrome Coronavirus Entry as a Target of Antiviral Therapies Jens H Kuhn, Wenhui Li, Sheli R Radoshitzky, Hyeryun Choe, Michael Farzan
17 [GO] 2022―Apr―14 Protection of Mammalian Cells from Severe Acute Respiratory Syndrome Coronavirus Infection by Equine Neutralizing Antibody Xiliang Wang, Bing Ni, Xinan Du, Guangyu Zhao, Wenda Gao, Xinfu Shi, et al. (+12)
18 [GO] 2022―Apr―14 Probing the Structure of the Sars Coronavirus Using Scanning Electron Microscopy Yun Lin, Xiyun Yan, Wuchun Cao, Chaoying Wang, Jing Feng, Jinzhu Duan, Sishen Xie
19 [GO] 2022―Apr―14 Safety and Immunogenicity from a Phase I Trial of Inactivated Severe Acute Respiratory Syndrome Coronavirus Vaccine Jiang-Tao Lin, Jian-San Zhang, Nan Su, Jian-Guo Xu, Nan Wang, Jiang-Ting Chen, et al. (+21)
20 [GO] 2022―Apr―14 Inhibition of Replication and Infection of Severe Acute Respiratory Syndrome-Associated Coronavirus with Plasmid-Mediated Interference RNA Bing Ni, Xinfu Shi, Yang Li, Wenda Gao, Xiliang Wang, Yuzhang Wu
21 [GO] 2022―Apr―14 Human Coronaviruses: What Do They Cause? Lia Van Der Hoek
22 [GO] 2022―Apr―14 Neuraminidase Inhibitors and their Role in Avian and Pandemic Influenza Martin Crusat, Menno D De Jong
23 [GO] 2022―Apr―14 Discovery and Characterization of the 1918 Pandemic Influenza Virus in Historical Context Jeffery K Taubenberger, Johan V Hultin, David M Morens
24 [GO] 2022―Mar―07 Antiviral prophylaxis for hepatitis B virus in COVID-19 patients treated with immunosuppressive drug therapy Antonio Mastroianni, Sonia Greco, Luciana Chidichimo, Maria Vittoria Mauro, Filippo Urso, Valeria Vangeli
25 [GO] 2022―Mar―02 Journey of remdesivir from the inhibition of hepatitis C virus to the treatment of COVID-19 Tomas Cihlar, Richard L. Mackman
26 [GO] 2022―Feb―26 Herpes simplex virus reactivation in patients with COVID-19 and acute respiratory distress syndrome: a prospective cohort study Alessandro F Chiesa, Micol Pallanza, Gladys Martinetti, Fabio Lanzi, Marco Previsdomini, Alberto Pagnamenta, Luigia Elzi
27 [GO] 2021―Oct―19 Real-life findings on the impact of the COVID-19 pandemic on HIV care Arturo Ciccullo, Gianmaria Baldin, Alberto Borghetti, Simona Di Giambenedetto
28 [GO] 2021―Sep―02 Comparative outcomes of lopinavir/ritonavir and hydroxychloroquine for the treatment of COVID-19 with mild-to-moderate severity: A retrospective observational study Jeong Eun Lee, Soon Ok Lee, Jeonghun Heo, Dong Wan Kim, Mi Ran Park, Hyunjin Son, et al. (+4)
29 [GO] 2021―Mar―11 The protease inhibitor lopinavir, boosted with ritonavir, as treatment for COVID-19: a rapid review Jienchi Dorward, Oghenekome Gbinigie, Ting Cai, Nia W Roberts, Nigel Garrett, Gail Hayward, Christopher C Butler
30 [GO] 2021―Feb―22 COVID-19 and hepatitis B infection Saleh A Alqahtani, Maria Buti
31 [GO] 2021―Jan―18 Early low-molecular-weight heparin administration is associated with shorter time to SARS-CoV-2 swab negativity Mattia Trunfio, Elena Salvador, Alberto Gaviraghi, Sabrina Audagnotto, Letizia Marinaro, Ilaria Motta, et al. (+6)
32 [GO] 2020―Aug―03 Evaluation of drugs for potential repurposing against COVID-19 using a tier-based scoring system Michael A Jarvis, Frederick A Hansen, Kyle Rosenke, Elaine Haddock, Christopher Rollinson, Simon Rule, et al. (+3)
33 [GO] 2020―Jun―26 SARS-CoV-2 and HIV protease inhibitors: why lopinavir/ritonavir will not work for COVID-19 infection Elise J Smolders, Lindsey HM te Brake, David M Burger
34 [GO] 2020―Jun―04 Combination antiviral therapy with lopinavir/ritonavir, arbidol and interferon-α1b for COVID-19Combination antiviral therapy with lopinavir/ritonavir, arbidol and interferon-α1b for COVID-19 Xiangyang Xie, Yuanliang Jiang, Yuan Zeng, Hui Liu
 [1] 

34 Results       Page 1


[de][en]

Last change 2025―Jul―29 14:55:09 UTC

© Daten-Quadrat 2022       Done in 0.004 sec